Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.048 | -0.097 | -0.074 | -0.15 |
| % Growth | 50.3% | -31.1% | 50.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |